Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Blood (2023) 142 (Supplement 1): 1800.

https://doi.org/10.1182/blood-2023-173132

Published: 2023

Journal Articles

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Blood (2023) 142 (Supplement 1): 445.

https://doi.org/10.1182/blood-2023-181571

Published: 2023

Journal Articles

Interleukin 10 (IL10) and IL15 Significantly Decreased in Chronic Myeloid Leukemia Patients Presenting with Tyrosine Kinase Inhibitor (TKI) Withdrawal Syndrome (TWS). Results from the Prospective, Explorative and Multicenter « Kiwis » Study Designed for TWS. Clinicaltrial.Gov ID: NCT03996096; Study Number: 18-206

Hyacinthe A. Johnson-Ansah, Anaïs Briant, Amandine Charbonnier, Nathalie Cambier, Gandhi Laurent Damaj, Pascal Lenain, Alexandra Henry, Jean-Jacques Parienti, David Guenet, Anne-Claire GAC Besnard, Baptiste Delapierre, Franck E. Nicolini, Brigitte Le Mauff, Marc G. Berger

Blood (2023) 142 (Supplement 1): 6335.

https://doi.org/10.1182/blood-2023-177651

Published: 2023

Journal Articles

Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase” in Patients with TKI-Resistant or Intolerant CML

Emilie Cayssials, Gabriel Etienne, Ali G Turhan, Philippe Rousselot, Valerie Coiteux, Marc G. Berger, Francoise Huguet, Agnes Guerci-Bresler

Blood (2022) 140 (Supplement 1): 6776–6777.

https://doi.org/10.1182/blood-2022-166111

Published: 2022

Journal Articles

Splenomegaly Study (SMS): Which Etiologies for Unexplained Splenomegalies?

Guillaume Denis, Louis Terriou, Thomas Séné, Regis Costello, Martin Michaud, Claudia Hellé, Audrey Lagadec, Frédéric Bauduer, Laurence Sanhes, Christian Rose, Geoffrey Urbanski, Marc G. Berger

Blood (2021) 138 (Supplement 1): 2991.

https://doi.org/10.1182/blood-2021-148322

Published: 2021

Journal Articles

Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML

Agnès Guerci, MD PhD, Emilie Cayssials, MD, Philippe Rousselot, MD PhD, Francoise Huguet, MD, Valerie Coiteux, MD, Marc G. Berger, MD PhD, Gabriel Etienne, MD PhD, Ali G Turhan, MD PhD

Blood (2019) 134 (Supplement_1): 5908.

https://doi.org/10.1182/blood-2019-122769

Published: 2019

Journal Articles

Prediction of One-Year Molecular Response to Imatinib at Diagnosis of Chronic Myeloid Leukemia By Scoring Gene Expression Levels of Antioxidant Enzymes

Frederic Picou, PhD, Jean-Claude Chomel, PharmD PhD, Marie Christine Bene, PharmD, Marc G. Berger, MD PhD, Thierry Fest, Valerie Ugo, MD PhD, Eric Lippert, MD PhD, Marion Socco-Luca, Martine Delain, MD, Marie-Helene Estienne, PharmD, Olivier Herault, MD PhD

Blood (2018) 132 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2018-99-118297

Published: 2018

Journal Articles

The Challenge of Unexplained Splenomegalies: Preliminary Data of the French Prospective Multi-Center Splenomegaly Study (SMS)

Guillaume Denis, MD, Laurence Sanhes, MD, Jean-Marc Ziza, MD PhD, Frederic Bauduer, MD PhD, Marc G. Berger, MD PhD, Regis T. Costello, MD PhD, Kawkab Mehdi, Martin Michaud, MD, Geoffrey Urbanski, MD, Christian Rose, MD PhD

Blood (2018) 132 (Supplement 1): 4815.

https://doi.org/10.1182/blood-2018-99-113123

Published: 2018

Journal Articles

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Blood (2018) 132 (Supplement 1): 48.

https://doi.org/10.1182/blood-2018-99-113058

Published: 2018

Journal Articles

Outcome after Midam Regimen and Impact of Post-Remission Strategy in Patients with Relapsing or Refractory Acute Myeloid Leukemia

Salem Bahashwan, MD, Cécile Moluçon-Chabrot, MD PhD, Eric Hermet, MD, Aurélie Ravinet, MD, Aurore Douge, Lauren Veronese, MD PhD, Andrei Tchirkov, MD PhD, Richard Lemal, MD, Marc G. Berger, MD PhD, Olivier Tournilhac, MD PhD, Jacques-Olivier Bay, MD PhD, Romain Guieze, MD PhD

Blood (2017) 130 (Supplement 1): 3900.

https://doi.org/10.1182/blood.V130.Suppl_1.3900.3900

Published: 2017

Journal Articles

Mast Cell Density and Its Clinical Relevance in Waldenstrom's Macroglobulinemia

Richard Lemal, MD, Stephanie Poulain, MD PhD, Albane Ledoux Pilon, MD, Lauren Veronese, MD PhD, Andrei Tchirkov, MD PhD, Benjamin Lebecque, Jacques-Olivier Bay, MD PhD, Frederic Charlotte, MD, Marc G. Berger, MD PhD, Catherine Godfraind, MD PhD, Loic Ysebaert, MD PhD, Frederic Davi, Veronique Leblond, Olivier Hermine, MD PhD, Romain Guieze, MD PhD, Franck Pages, MD PhD, Olivier Tournilhac, MD PhD

Blood (2017) 130 (Supplement 1): 4028.

https://doi.org/10.1182/blood.V130.Suppl_1.4028.4028

Published: 2017

Journal Articles

Dynamic of Telomeric Parameters in Relapsing or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL), an Analysis of the Filo ICLL001 Bomp Trial

Blood (2017) 130 (Supplement 1): 4285.

https://doi.org/10.1182/blood.V130.Suppl_1.4285.4285

Published: 2017

Journal Articles

No Influence of BCR-ABL1 Transcript Types e13a2 and e14a2 on MR4.5 in Patients with Chronic Myeloid Leukemia Treated with Nilotinib Frontline

Alexis Genthon, Franck Emmanuel Nicolini, MD PhD, Marc G. Berger, MD PhD, Sandrine Saugues, Alexandre Janel, Denis Guyotat, Sandrine Hayette, MD, Lydia Campos, Pascale Flandrin-Gresta, MD

Blood (2017) 130 (Supplement 1): 2907.

https://doi.org/10.1182/blood.V130.Suppl_1.2907.2907

Published: 2017

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

Journal Articles

Hypercoagulability in Cirrhotic Patients; Impact of Acquired Protein C Deficiency and Factor VIII Increase in Low Sensitivity to Thrombomodulin

Thomas Sinegre, PharmD, Cedric Duron, MD, Marc G. Berger, MD PhD, Armand Abergel, MD PhD, Aurelien Lebreton, MD PhD

Blood (2016) 128 (22): 1420.

https://doi.org/10.1182/blood.V128.22.1420.1420

Published: 2016

Journal Articles

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

Blood (2016) 128 (22): 787.

https://doi.org/10.1182/blood.V128.22.787.787

Published: 2016

Journal Articles

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Blood (2016) 128 (22): 789.

https://doi.org/10.1182/blood.V128.22.789.789

Published: 2016

Journal Articles

Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort

Marc G Berger, MD PhD Professor, Bruno Pereira, PhD, Charlotte Oris, PhD, Sandrine Saugues, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Laurence Legros, MD, Martine Escoffre-Barbe, Franck E. Nicolini, MD PhD, Philippe Rousselot, MD PhD Professor, Delphine Rea, MD PhD, Joelle Guilhot, PhD, Marie Zénut, MD PhD, Agnès Guerci, MD PhD, Stephane Giraudier, MD PhD Professor, Francois-Xavier Mahon, MD PhD Professor

Blood (2015) 126 (23): 137.

https://doi.org/10.1182/blood.V126.23.137.137

Published: 2015

Journal Articles

Soluble Endothelial Protein C Receptor (sEPCR) Is Increased in Cirrhotic Patients. A Possible Role in Procoagulant Imbalance?

Thomas Sinegre, PharmD, Cedric Duron, MD, Ahmed Bouras, Arnaud Serres, Marc G Berger, MD PhD Professor, Anne-Françoise Sapin, Armand Abergel, MD PhD, Aurelien Lebreton, MD PhD

Blood (2015) 126 (23): 1080.

https://doi.org/10.1182/blood.V126.23.1080.1080

Published: 2015

Journal Articles

Epicatechin Impact on Primary Hemostasis, Coagulation and Fibrinolysis

Thomas Sinegre, PharmD, André Mazur, PhD, Marc G Berger, MD PhD Professor, Dragan Milenkovic, PhD, Anne-Françoise Sapin, Christine Morand, PhD, Aurelien Lebreton, MD PhD

Blood (2015) 126 (23): 4677.

https://doi.org/10.1182/blood.V126.23.4677.4677

Published: 2015

NARROW

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase” in Patients with TKI-Resistant or Intolerant CML

Splenomegaly Study (SMS): Which Etiologies for Unexplained Splenomegalies?

Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML

Prediction of One-Year Molecular Response to Imatinib at Diagnosis of Chronic Myeloid Leukemia By Scoring Gene Expression Levels of Antioxidant Enzymes

The Challenge of Unexplained Splenomegalies: Preliminary Data of the French Prospective Multi-Center Splenomegaly Study (SMS)

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Outcome after Midam Regimen and Impact of Post-Remission Strategy in Patients with Relapsing or Refractory Acute Myeloid Leukemia

Mast Cell Density and Its Clinical Relevance in Waldenstrom's Macroglobulinemia

Dynamic of Telomeric Parameters in Relapsing or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL), an Analysis of the Filo ICLL001 Bomp Trial

No Influence of BCR-ABL1 Transcript Types e13a2 and e14a2 on MR4.5 in Patients with Chronic Myeloid Leukemia Treated with Nilotinib Frontline

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Hypercoagulability in Cirrhotic Patients; Impact of Acquired Protein C Deficiency and Factor VIII Increase in Low Sensitivity to Thrombomodulin

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort

Soluble Endothelial Protein C Receptor (sEPCR) Is Increased in Cirrhotic Patients. A Possible Role in Procoagulant Imbalance?

Epicatechin Impact on Primary Hemostasis, Coagulation and Fibrinolysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only